Liquidia Corporation
22.45-0.70 (-3.02%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · LQDA · USD
Key Stats
Market Cap
1.93BP/E (TTM)
-Basic EPS (TTM)
-1.82Dividend Yield
0%Recent Filings
8-K
YUTREPIA launch exceeds expectations
Liquidia Corporation launched YUTREPIA on June 1, 2025, following FDA approval for PAH and PH-ILD, achieving over 900 unique prescriptions and 550 patient starts by August 8. Interim ASCENT trial data showed median 6MWD improvements of 31.5 meters at Week 16 with no drug-related discontinuations, bolstering tolerability. Q2 net product revenue hit $6.5 million, but SG&A expenses surged 95% to $38.8 million amid commercialization, yielding a $41.6 million net loss. Ongoing litigation with United Therapeutics poses sales risks.
10-Q
Q2 FY2025 results
Liquidia Corporation reported Q2 2025 results with $6.5M product sales from YUTREPIA launch, total revenue $8.8M (up 142% YoY), net loss $41.6M (up 45% YoY), cash $173.4M, and debt $193.6M. Key highlights include FDA approval for YUTREPIA in May 2025, $50M HCR funding, ongoing litigation risks with United Therapeutics, and focus on commercialization and L606 development.
8-K
Liquidia appoints new CAO
Liquidia Corporation appointed Dana Boyle as Chief Accounting Officer effective July 1, 2025, promoting her from Senior Vice President, Finance and Controller since 2021. She'll earn a $425,000 base salary, a 50% target bonus, and RSUs worth $300,000 vesting over four years. Boyle brings prior controller experience at Aerami Therapeutics and Aralez Pharmaceuticals. This internal move bolsters accounting leadership amid biotech regulatory demands.
8-K
Liquidia receives $50M funding boost
Liquidia Corporation secured $50 million in additional funding from HealthCare Royalty Partners on June 23, 2025, under the amended HCR Agreement, triggered by the court's denial of United Therapeutics' injunction request on May 30 and the first commercial shipment of YUTREPIA on June 2. This brings total funding to $175 million of $200 million available, with proceeds earmarked to accelerate YUTREPIA's launch, advance clinical trials, and expand manufacturing. Yet $25 million more hinges on hitting $100 million in net sales by June 30, 2026. Legal proceedings could still delay commercialization.
8-K
Liquidia leases manufacturing facility
Liquidia Corporation's subsidiary inked a lease on June 16, 2025, for a 70,131-square-foot manufacturing facility in Morrisville, North Carolina, running through November 1, 2036, with two five-year extension options and a right of first offer on adjacent space. Base rent kicks in at $260,069.13 monthly from May 1, 2026, escalating 3% annually after the first year, but abated for the initial six months while covering operating expenses. This secures long-term production capacity. Yet risks lurk in standard lease covenants.
ALT
Altimmune, Inc.
4.00-0.06
LEXX
Lexaria Bioscience Corp.
0.96+0.01
LGND
Ligand Pharmaceuticals Incorpor
184.52-4.35
LIANY
LianBio
0.07+0.00
LSTA
Lisata Therapeutics, Inc.
2.66-0.12
PULM
Pulmatrix, Inc.
4.88+0.01
RNTX
Rein Therapeutics, Inc.
1.55+0.23
TBPH
Theravance Biopharma, Inc.
14.17+0.07
TRVI
Trevi Therapeutics, Inc.
10.58+0.05
UTHR
United Therapeutics Corporation
455.32+39.98